Kazumasa Kamei

Jul 18, 2023 | futuremedicine.com | Ataru Igarashi |Kanae Togo |Yasuhiro Kobayashi |Kazumasa Kamei

Future VirologyAhead of PrintResearch ArticleOpen AccessAbstractObjective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants.